City

Clinical trials near City of Saint Peters, United States

Active studies with a listed research site in City of Saint Peters, United States.

16active studies

6recruiting now

16countries represented

137largest site network

Current studies

Status and location data reflect the registry snapshot built 2026-09-08. Verify the original record before contacting a site.

Recruiting nowPhase 2

A Master Protocol Study (LY900038) of Multiple Intervention-Specific-Appendices (ISAs) in Adult Participants With Obesity or Overweight

Obesity, OverweightCondition

LY3305677, LY3841136Treatment

Argentina, United States56 locations

Eli Lilly and CompanySponsor

Updated 2026-09-08 · NCT06143956See eligibility →

Recruiting nowPhase 2

A Study to Test Whether BI 3034701 Helps People to Lose Weight Who Live With Obesity or Overweight

Obesity, OverweightCondition

BI 3034701, Placebo matching BI 3034701Treatment

Australia, Canada54 locations

Boehringer IngelheimSponsor

Updated 2026-09-03 · NCT07662122See eligibility →

Recruiting nowPhase 2

Safety and Efficacy of ABBV-295 in Adults With Obesity or Overweight With Weight-Related Comorbidities

Obesity, OverweightCondition

ABBV-295, PlaceboTreatment

Puerto Rico, United States38 locations

AbbVieSponsor

Updated 2026-09-03 · NCT07752979See eligibility →

Recruiting nowPhase 3

A Study of Aleniglipron in Adults With Obesity or Overweight and Type 2 Diabetes Mellitus (ACCOMPLISH-2)

Obesity, OverweightCondition

aleniglipron, aleniglipronTreatment

United States74 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-09-01 · NCT07654374See eligibility →

Recruiting nowPhase 2

A Study to Investigate Weight Management With Macupatide and Eloralintide, Alone or in Combination, in Adult Participants With Obesity or Overweight

Overweight, ObesityCondition

Macupatide, EloralintideTreatment

United States40 locations

Eli Lilly and CompanySponsor

Updated 2026-08-06 · NCT07589608See eligibility →

Recruiting nowPhase 2

A Research Study Comparing Different Ways of Increasing the Dose of NNC0662-0419 in Participants With Obesity

ObesityCondition

NNC0662-0419, SemaglutideTreatment

Puerto Rico, United States25 locations

Novo Nordisk A/SSponsor

Updated 2026-07-10 · NCT07639021See eligibility →

Opening soonPhase 3

AMAZE 9: A Research Study Investigating How Well Zenagamtide Tablets Help People With Excess Body Weight Lose Weight

Overweight, ObesityCondition

zenagamtide, PlaceboTreatment

United States37 locations

Novo Nordisk A/SSponsor

Updated 2026-08-25 · NCT07720271See eligibility →

Active, not recruitingPhase 3

Weight Loss in People Living With Overweight or Obesity Following Treatment With Cagrilintide

Obesity, OverweightCondition

Cagrilintide, PlaceboTreatment

Argentina, Australia40 locations

Novo Nordisk A/SSponsor

Updated 2026-08-06 · NCT07220642See eligibility →

Active, not recruitingPhase 3

A Research Study to Look at How Well CagriSema Helps People Living With Obesity Lose Weight and Maintain Weight Loss in the Long-term

ObesityCondition

CagriSema (Cagrilintide B and Semaglutide I), Placebo matched to CagriSema (Cagrilintide B and Semaglutide I)Treatment

United States46 locations

Novo Nordisk A/SSponsor

Updated 2026-07-24 · NCT07011667See eligibility →

Active, not recruitingPhase 3

A Study of Retatrutide (LY3437943) Compared to Tirzepatide (LY3298176) in Adults Who Have Obesity

ObesityCondition

Retatrutide, TirzepatideTreatment

Argentina, Germany65 locations

Eli Lilly and CompanySponsor

Updated 2026-07-20 · NCT06662383See eligibility →

Active, not recruitingPhase 2

A Study to Investigate Weight Management With LY3841136 and Tirzepatide (LY3298176), Alone or in Combination, in Adult Participants With Obesity or Overweight With Type 2 Diabetes

Obesity, OverweightCondition

LY3841136, TirzepatideTreatment

Argentina, United States52 locations

Eli Lilly and CompanySponsor

Updated 2026-07-17 · NCT06603571See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Type 2 Diabetes Phase 3 (VANQUISH 2)

Weight LossCondition

VK2735Treatment

Puerto Rico, United States127 locations

Viking Therapeutics, Inc.Sponsor

Updated 2026-04-07 · NCT07104383See eligibility →

Active, not recruitingPhase 2

Taldefgrobep Alfa in Adults With Overweight and Obesity

Obesity, OverweightCondition

Taldefgrobep Alfa, PlaceboTreatment

United States20 locations

Biohaven Therapeutics Ltd.Sponsor

Updated 2026-03-20 · NCT07281495See eligibility →

Active, not recruitingPhase 2

Aleniglipron Phase 2 Body Composition Study

Obesity, Overweight, or Chronic Weight ManagementCondition

aleniglipron or placeboTreatment

United States11 locations

Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure TherapeuticsSponsor

Updated 2026-03-03 · NCT07169942See eligibility →

Active, not recruitingPhase 3

A Research Study to Look Into the Long-term Effect on Weight Loss of CagriSema in People With Obesity

ObesityCondition

Cagrilintide, SemaglutideTreatment

Belgium, Canada36 locations

Novo Nordisk A/SSponsor

Updated 2026-01-20 · NCT06780449See eligibility →

Active, not recruitingPhase 3

VK2735 for Weight Management Phase 3

Weight LossCondition

VK2735Treatment

Puerto Rico, United States137 locations

Viking Therapeutics, Inc.Sponsor

Updated 2025-11-24 · NCT07104500See eligibility →

How current is this page?

The page is rebuilt from the public registry feed. Each trial card shows the registry update date. Recruitment can still change between builds.

Does appearing here mean I qualify?

No. These pages are discovery indexes. Only a study team can confirm eligibility after reviewing the complete protocol criteria.

Clinical trials near City of Saint Peters, United States

Current studies

Related cities